Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Trends Immunol. 2022 Apr;43(4):262-264. doi: 10.1016/j.it.2022.02.006. Epub 2022 Mar 10.
In a recent report, Orecchioni et al. identify a role for the olfactory receptor (OR) Olfr2 and its human ortholog OR6A2 in atherosclerosis. Vascular macrophage Olfr2 binds octanal, a product of lipid peroxidation, activating the NLRP3 inflammasome and IL-1β secretion, and driving atherosclerosis pathology. Thus, OR6A2 inhibitors may represent a promising therapy for atherosclerosis.
在最近的一份报告中，Orecchioni 等人确定了嗅觉受体 (OR) Olfr2 及其人类同源物 OR6A2 在动脉粥样硬化中的作用。血管巨噬细胞 Olfr2 结合脂质过氧化产物辛醛，激活 NLRP3 炎性体和 IL-1β 的分泌，从而驱动动脉粥样硬化的病理过程。因此，OR6A2 抑制剂可能是动脉粥样硬化的一种有前途的治疗方法。
